Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients
DOI:
https://doi.org/10.53778/pjkd40353Ključne besede:
Rejection, kidney transplant, acute rejection, chronic rejection, antibody mediated rejection, complement,, plasmapheresis, Bortezomib,, Rituximab, Eculizumab, TocilizumabPovzetek
Chronic antibody mediated rejection (AMR) is a major cause of allograft failure1,2. Chronic AMR clinically presents with proteinuria and gradual decline in renal function. The underlying mechanisms of AMR include both antibody mediated complement-dependent cytotoxicity, complement-independent cellular cytotoxicity and other mechanisms. The purpose of this review is to appraise recent literature on diagnosis, treatment and prevention of chronic AMR.
Prenosi
Objavljeno
2021-01-31
Številka
Rubrika
Review Article
Licenca
Avtorske pravice (c) 2021 Salman Tahir Shafi
To delo je licencirano pod Creative Commons Priznanje avtorstva-Nekomercialno 4.0 mednarodno licenco.
Kako citirati
Update on Treatment and Prevention of Chronic Antibody Mediated Rejection in Renal Transplant Recipients. (2021). Pakistan Journal of Kidney Diseases, 4(03). https://doi.org/10.53778/pjkd40353
